CMV


ACTG launches A5383, clinical trial evaluating potential immunologic benefits of treating asymptomatic CMV in people living with HIV The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the initiation of A5383, a clinical trial evaluating whether the anti- cytomegalovirus (CMV) drug letermovir reduces inflammation when […]

A5383: ELICIT clinical trial of anti-CMV medication letermovir


Participant Summary Click here for a printable participant summary.   Title: A5355 – Phase II, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-based anti-Cytomegalovirus (CMV) Vaccine (Triplex®), in Adults with Both Human Immunodeficiency Virus (HIV)-1 and CMV Who Are on Potent Combination ART […]

A5355: a clinical trial of an anti-CMV vaccine